RAD51C and ovarian carcinoma: In ovarian cancer, analysis of samples from the ARIEL2 trial of rucaparib maintenance therapy found RAD51C and RAD51D mutations as well as high-level BRCA1 promoter methylation to be associated with PARPi sensitivity (17).